drugset / Trial / NCT02435186
p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The study objective is to investigate the efficacy and safety of p53 combined with chemotherapy (cisplatin and paclitaxel) in treatment of recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer.
Timeline
- Start
- 2015-06
- Primary completion
- 2018-08
- Completion
- 2018-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | p53 gene | Unknown | 2e+12 vg | Other |
| Background | Cisplatin | Other / unclassified | 150 mg/m2 | Other |
| Background | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |